| Outcome Measures: |
Primary: Number of Participants Experiencing Adverse Events (AEs) On Study, An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the study treatment, was also an adverse event., From Day 1 through the end of poststudy period (up to Day 25)|Number of Participants Who Discontinued Treatment Due to an AE, An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the study treatment, was also an adverse event., From Day 1 through the end of poststudy period (up to Day 25) | Secondary: Least Squares Mean Change From Baseline in 24-Hour Weighted Mean Glucose (WMG), Plasma glucose concentration was determined using a glucometer and measured before drug was given to establish a baseline fasting plasma glucose concentration. Plasma glucose concentrations were then measured every \~30 minutes over a 24 hour period after the Day 1 dose (First Dosing Day) and after the Day 10 dose (Last Dosing Day) to obtain a weighted mean average value for Day 1 and for Day 10. Results were expressed as the change from baseline to the Day 1 weighted average (First Dosing Day), and as the change from baseline to the Day 10 weighted average (Last Dosing Day)., Day -1 (pre-dose baseline), Day 1 (First Dosing Day), Day 10 (Last Dosing Day)
|
